© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > BMS-986242
<< Back to January
oral IDO1 inhibitor
clinical candidate in Ph. I/II combo for cancer
reversed amide of linrodostat
ACS Med. Chem. Lett., Jan. 28, 2021
Bristol Myers Squibb, Lawrence Township, NJ
The BMS IDO1 inhibitor, BMS-986242, is a clinical candidate in a Ph. I/II study in combination with nivolumab for cancer. Like me, you probably had to look twice at…
Unlock this content with a Premium membership to read it now.